Shannon L. Devers - 03 Mar 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
EVP, Chief Human Resources Ofc
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers
Issuer symbol
IONS
Transactions as of
03 Mar 2026
Net transactions value
-$1,596,433
Form type
4
Filing time
05 Mar 2026, 18:14:06 UTC
Previous filing
23 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Devers Shannon L. EVP, Chief Human Resources Ofc 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers 05 Mar 2026 0002037721

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise +3,510 +16% $37.58* 26,051 03 Mar 2026 Direct
transaction IONS Common Stock Options Exercise +3,760 +14% $40.85* 29,811 03 Mar 2026 Direct
transaction IONS Common Stock Options Exercise +5,500 +18% $34.69* 35,311 03 Mar 2026 Direct
transaction IONS Common Stock Options Exercise +6,951 +20% $32.60* 42,262 03 Mar 2026 Direct
transaction IONS Common Stock Options Exercise +385 +0.91% $52.87* 42,647 03 Mar 2026 Direct
transaction IONS Common Stock Sale $1,133,006 -14,321 -34% $79.12 28,326 03 Mar 2026 Direct F1, F2
transaction IONS Common Stock Sale $402,395 -5,030 -18% $80.00 23,296 03 Mar 2026 Direct F1, F3
transaction IONS Common Stock Sale $61,032 -755 -3.2% $80.84 22,541 03 Mar 2026 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise -6,951 -88% $0.000000* 928 03 Mar 2026 Common Stock 6,951 $32.60 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise -5,500 -25% $0.000000* 16,500 03 Mar 2026 Common Stock 5,500 $34.69 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise -3,510 -38% $0.000000* 5,744 03 Mar 2026 Common Stock 3,510 $37.58 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise -3,760 -25% $0.000000* 11,280 03 Mar 2026 Common Stock 3,760 $40.85 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise -385 -4.2% $0.000000* 8,877 03 Mar 2026 Common Stock 385 $52.87 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.61 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.68 to $80.675 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.